Radiomics of Mp-MRI Assessing NAC Outcome in Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Breast Cancer
- Multi-parametric MRI
- Neoadjuvant Chemotherapy
- Radiomics
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Younger than 125 years
- Gender
- Only males
Description
Patients undergo multiparametric MRI (including T2WI, DWI and DCE-MRI) at baseline, after 2 courses of neoadjuvant chemotherapy, and prior to the surgery at least 8 weeks after the treatment procedure. Patients undergo biopsy test in one week after the baseline MRI scan to detect the biomarkers incl...
Patients undergo multiparametric MRI (including T2WI, DWI and DCE-MRI) at baseline, after 2 courses of neoadjuvant chemotherapy, and prior to the surgery at least 8 weeks after the treatment procedure. Patients undergo biopsy test in one week after the baseline MRI scan to detect the biomarkers including ER, PR, Her-2 and Ki-67, which can be used to select the treatment plan referring to the NCCN clinical guidelines. After the surgery, responses to neoadjuvant chemotherapy are determined according to the histopathologically examination of the surgically resected specimens. After completion of treatment procedure, patients are followed up for 5 years.
Tracking Information
- NCT #
- NCT03592004
- Collaborators
- Guangdong Provincial People's Hospital
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Beijing Friendship Hospital
- Yunnan Cancer Hospital
- Liaoning Tumor Hospital & Institute
- First Hospital of China Medical University
- Affiliated Hospital of Hebei University
- Investigators
- Principal Investigator: Jie Tian, Doctor Chinese Academy of Sciences
Get Well Soon